Identification of Cytochrome P450 Enzymes Responsible for Oxidative Metabolism of Synthetic Cannabinoid (1-Hexyl-1H-Indol-3-yl)-1-naphthalenyl-methanone (JWH-019)

被引:0
|
作者
Tran, Ngoc [1 ]
Fantegrossi, William E. [2 ]
McCain, Keith R. [3 ]
Wang, Xinwen [4 ]
Fujiwara, Ryoichi [1 ,4 ]
机构
[1] Univ Arkansas Med Sci, Coll Pharm, Dept Pharmaceut Sci, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA
[3] Univ Arkansas Med Sci, Coll Pharm, Dept Pharm Practice, Little Rock, AR 72205 USA
[4] Northeast Ohio Med Univ, Coll Pharm, Dept Pharmaceut Sci, Rootstown, OH 44272 USA
关键词
synthetic cannabinoids; xenobiotic metabolism; cytochrome P450; oxidation; metabolic activation; HUMAN LIVER-MICROSOMES; UNITED-STATES; IN-VITRO; TOXICITY; P450; PROFILE; CYP2J2; HIGHS; CB1;
D O I
10.3390/catal13061008
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
(1-Hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone (JWH-019) is one of the second-generation synthetic cannabinoids which as a group have been associated with severe adverse reactions in humans. Although metabolic activation can be involved in the mechanism of action, the metabolic pathway of JWH-019 has not been fully investigated. In the present study, we aimed to identify the enzymes involved in the metabolism of JWH-019. JWH-019 was incubated with human liver microsomes (HLMs) and recombinant cytochrome P450s (P450s or CYPs). An animal study was also conducted to determine the contribution of the metabolic reaction to the onset of action. Using an ultra-performance liquid chromatography system connected to a single-quadrupole mass detector, we identified 6-OH JWH-019 as the main oxidative metabolite in HLMs supplemented with NADPH. JWH-019 was extensively metabolized to 6-OH JWH-019 in HLMs with the K-M and V-max values of 31.5 & mu;M and 432.0 pmol/min/mg. The relative activity factor method estimated that CYP1A2 is the primary contributor to the metabolic reaction in the human liver. The animal study revealed that JWH-019 had a slower onset of action compared to natural and other synthetic cannabinoids. CYP1A2 mediates the metabolic activation of JWH-019, contributing to the slower onset of its pharmacological action.
引用
收藏
页数:12
相关论文
共 31 条
  • [21] Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist
    Ghosal, Anima
    Lu, Xiaowen
    Penner, Natalia
    Gao, Lan
    Ramanathan, Ragu
    Chowdhury, Swapan K.
    Kishnani, Narendra S.
    Alton, Kevin B.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (01) : 30 - 38
  • [22] Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic Acid (TSU-68)
    Kitamura, Ryuichi
    Asanoma, Hisae
    Nagayama, Sekio
    Otagiri, Masaki
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (06) : 1003 - 1009
  • [23] CYTOCHROME-P-450 3A4 (NIFEDIPINE OXIDASE) IS RESPONSIBLE FOR THE C-OXIDATIVE METABOLISM OF 1-NITROPYRENE IN HUMAN LIVER MICROSOMAL SAMPLES
    SILVERS, KJ
    CHAZINSKI, T
    MCMANUS, ME
    BAUER, SL
    GONZALEZ, FJ
    GELBOIN, HV
    MAUREL, P
    HOWARD, PC
    CANCER RESEARCH, 1992, 52 (22) : 6237 - 6243
  • [24] Metabolism of CJ-036878, N-(3-phenethoxybenzyl)-4-hydroxybenzamide, in liver microsomes and recombinant cytochrome P450 enzymes:: metabolite identification by LC-UV/MSn and 1H-NMR
    Nishida, H.
    Hirai, H.
    Emoto, C.
    Iwasaki, K.
    XENOBIOTICA, 2007, 37 (12) : 1394 - 1407
  • [25] Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine, by human cytochrome P450 enzymes
    Cherstniakova, SA
    Bi, DQ
    Fuller, DR
    Mojsiak, JZ
    Collins, JM
    Cantilena, LR
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (09) : 1216 - 1220
  • [26] METABOLISM OF 11-DEOXYCORTISOL BY CYTOCHROME P450(11-BETA) - IDENTIFICATION OF REACTION-PRODUCTS BY H-1-NMR AND LC/MS-APCI METHOD
    OHTA, M
    FUJII, S
    NONAKA, Y
    OKAMOTO, M
    ENDOCRINE RESEARCH, 1995, 21 (1-2) : 477 - 481
  • [27] Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H-benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1: β-oxidation as a potential augmenting pathway for inhibition
    Kowalski, John P.
    Pelletier, Robert D.
    McDonald, Matthew G.
    Kelly, Edward J.
    Rettie, Allan E.
    XENOBIOTICA, 2021, 51 (08) : 901 - 915
  • [28] Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile
    Velaparthi, Upender
    Liu, Peiying
    Balasubramanian, Balu
    Carboni, Joan
    Attar, Ricardo
    Gottardis, Marco
    Li, Aixin
    Greer, Ann
    Zoeckler, Mary
    Wittman, Mark D.
    Vyas, Dolatrai
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (11) : 3072 - 3076
  • [29] Identification of cytochrome P450 enzymes critical for lung tumorigenesis by the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridy1)-1-butanone (NNK): insights from a novel Cyp2abfgs-null mouse
    Li, Lei
    Megaraj, Vandana
    Wei, Yuan
    Ding, Xinxin
    CARCINOGENESIS, 2014, 35 (11) : 2584 - 2591
  • [30] Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction
    Inami, Hiroshi
    Mizutani, Tsuyoshi
    Watanabe, Junko
    Hayashida, Hisashi
    Ito, Tomonori
    Terasawa, Takeshi
    Kontani, Toru
    Yamagishi, Hiroaki
    Usuda, Hiroyuki
    Aoyama, Naohiro
    Imamura, Emiko
    Ishikawa, Takeshi
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 87